Global Health Investment Advisors

Global Health Investment Advisors

Global Health Investment Advisors (GHIA) was established in 2012 to manage the Global Health Investment Fund (GHIF), a social impact vehicle incubated by the Bill & Melinda Gates Foundation and J.P. Morgan. Curtis L. Wander, a former pharmaceutical executive and venture investor, has served as Managing Director and Chief Investment Officer since the firm's inception. The firm operates from New York with an explicit mandate to bridge the financing gap between early-stage global health R&D and commercial scale-up. GHIA deploys capital primarily through its core GHIF mandate, targeting regulated life sciences companies developing drugs, vaccines, diagnostics, and medical devices for infectious diseases that disproportionately affect low- and middle-income countries. The strategy spans venture-stage equity, mezzanine debt, and structured royalty transactions. Confirmed portfolio positions include EuBiologics, a Korean vaccine manufacturer supplying oral cholera vaccines to UNICEF, and Medicines Development for Global Health, which gained FDA approval for moxidectin to treat river blindness. The firm also engineered the first social impact bond for infectious disease, a $30 million facility to fund a malaria vaccine candidate. Geographic coverage extends across Africa, Southeast Asia, and Latin America via grants from the Gates Foundation and Swedish Sida. The firm predominantly leads or co-leads its rounds, often alongside development finance institutions. The firm has raised and deployed over $230 million through its initial GHIF and a successor pooled vehicle, with operations supported by a team drawing expertise from both pharmaceutical development and institutional finance. In 2023, GHIA announced the first close of its second fund, targeting a broader remit to include pandemic preparedness alongside its historical focus on neglected diseases. The firm is affiliated with the GHIF Social Impact Fund, LP, a structure designed with layered capital stacks where philanthropic and government funders take first-loss positions to attract private institutional investors. Adjacent to the fund complex, the principals oversee related grant-funded technical assistance programs that de-risk pipeline assets before they become investment-grade. GHIA's structural differentiator is the explicit public-health contingency embedded in its limited partnership agreements: portfolio companies must agree to an access plan ensuring affordable pricing in low-income countries as a condition of investment. The firm further distinguishes itself by maintaining a grants-management capability that co-exists alongside the for-profit pooled funds, allowing it to use philanthropic capital to mature a pipeline asset to the point where the commercial fund can invest — a blended finance architecture rarely seen in life sciences venture firms this small.